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I - Introduction 
The role of public health is to ensure that the basic 
conditions required for people to be healthy are present. 
Until recently, public health focused mostly on 
environmental causes and risk factors for disease, such
as infections, cigarette smoking, diet, etc. Since th  
sequencing of the human genome has been completed, 
high hopes rest on the potential to prevent the impact of 
genetic risk factors or susceptibilities to disease. 
Advances in genetic knowledge and technology could 
be used to try to prevent disease and improve 
population health.  
The perceived role of genetics in public health is 
changing, as is the definition of what is a genetic 
disease. The role of genetics in public health is 
broadened if we consider all the diseases for which 
genetics might play a role, either by the presence of a
genetic susceptibility for the development of this 
disease or for response to treatment, or by the presence 
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of protective genetic factors, such as in resistance to 
infection.  
One day, it might be possible to determine for each 
individual which genetic susceptibilities and protective 
factors each individual possesses, and act accordingly 
to prevent the occurrence of disease. In the meantime, 
the role of genetics in public health is mostly limited to 
monogenic diseases.  
II - Populations targeted by public 
health genetics interventions 
Public health considers the overall health of the 
population as a group, and not the health of each 
individual. Since resources for public health 
interventions are limited, priorities need to be 
established to determine which interventions will be
most beneficial to the population as a whole. These 
priorities will be based on the characteristics of the 
disease, such as its prevalence, its severity, and 
treatment availability, as well as the amount of 
resources needed for the intervention.  
Monogenic diseases are rare. Is it justifiable to 
implement population-based interventions to identify a 
few rare cases of a particular genetic disease? There is 
no single right answer to this question. It depends on 
the burden these rare cases represent for society, on our 
ability to act to attenuate this burden, and on the value 
we place on obtaining an early diagnosis, compared to 
the complexity of detecting these cases and the amount 
of resources needed to detect them. For example, 
newborn screening for phenylketonuria is considered 
beneficial because it makes it possible for the children 
identified through screening, who would otherwise 
have developed severe mental retardation, to develop 
normally by following a special diet. In the majority of 
developed countries, all newborns are screened for 
phenylketonuria to detect a handful of cases, because 
the impact of treatment on these children’s potential 
ability to contribute to society is so great. On the other 
hand, similar newborn screening for Huntington 
disease is not being considered, because it is a late-
onset disease for which there is no treatment and no 
clear benefit to an early diagnosis. Screening would not 
change the impact of the disease on the affected 
individuals or its burden on society.  
To improve the yield of a screening program for a 
genetic disease, one option is to target a population at 
higher risk of disease, often the families of affected 
cases. This approach limits the amount of resources 
needed for screening and increases the yield of 
screening. It unfortunately is limited by the fact that 
many new cases of genetic disease occur in individuals 
with no family history who would not be identified by 
family-based screening. In some cases, ethnic groups 
can be the target population of screening programs, 
when prevalence of the disease in questions is 
particularly high in that ethnic group. For example, 
Ashkenaze Jewish populations are screened for Tay-
Sachs disease. In programs targeted at specific 
communities, it is important to ensure that the 
community is in favor of screening and that it does not 
become a source of stigmatization for the community.  
III - Ethical, legal, and social 
implications of public health genetic 
interventions 
III - 1. Use of genetic information: confidentiality 
and discrimination 
The issue of confidentiality of genetic information is 
frequently raised. Genetic information is different from 
other types of personal information found in a medical 
chart. First, genetic information does not change ov r 
time: the presence of a mutation or a polymorphism in 
an individual is immutable. Second, genetic 
information about one individual has implications not 
only for the individual in question, but also for his/ er 
family members, since the genetic abnormalities are 
heritable in most cases. In some cases, genetic 
information is used to confirm a clinical diagnosis, but 
it is increasingly used to confer a level of risk or 
susceptibility for the development a specific condition. 
In that context, it is not surprising that some are 
worried that information about a specific genetic 
susceptibility might be used by insurers or employers 
as a source of discrimination.  
III - 2. DNA banks 
Genetic research often requires the collection of DNA 
samples. Many DNA banks were formed from DNA 
samples collected for specific research projects or from 
blood samples collected for newborn screening. Once 
they have served their intended use, what should now 
be done with these samples? Who do they belong to? 
Can the researcher use them for other purposes without 
the consent of those who gave these samples? Can he 
only do it if he anonymizes the samples first? Or does 
the researcher need to contact each individual to renew 
his/her consent? To respect the autonomy of 
individuals who participated in previous research 
projects, it would be necessary to contact them again to 
obtain renewed consent before using their samples for 
other research projects. On the other hand, these 
samples are easily accessible and could be used to 
further scientific knowledge for the benefit of society 
without major negative impact on the individual who 
provided the sample, especially if the samples are 
anonymized. In some cases, the nature of the 
prospective research will also influence the decision to 
use or not use samples from a DNA bank. Researchers 
and ethicists all over the world are faced with these 
issues. Institutional review boards are assessing each 
research project based on its specific context, because 
no consensus has been reached for now on procedures 
for the use of DNA banks in research.  
III - 3. Prenatal diagnosis, assisted reproduction and 
embryo selection 
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Assisted reproduction has made it necessary to redefin  
fundamental concepts, such as paternity and maternity. 
We now use the terms biological mother, gestational 
mother (or surrogate mother), and social mother. We 
also differentiate between biological father and social 
father. Before DNA tests, paternity was always 
assumed, but it is now possible to determine with 
strong certainty whether an individual is or isn’t a 
given child’s biological father. In the past, maternity 
was simply attributed to the woman who had given 
birth to the child. But these days, it is possible for a 
woman to have an embryo conceived with her own 
eggs carried to term by another woman. The first 
woman is then the biological mother, and the second 
the gestational mother. The social mother will be th
one acting as a parent to the child in question.  
Assisted reproduction is not reserved for infertile 
couples anymore, but is also used by couple who want
to ensure that their child will be born without a specific 
hereditary disease, or even to make sure that their c ild 
will be a matched donor for an older sibling in need of 
a bone marrow transplant. Genetic tests performed on 
embryos make it possible to select only embryos that fit 
certain criteria. For now, this technology is mostly used 
to avoid the birth of children with severe hereditary 
childhood diseases, but it is feared that it opens the 
door to embryo selection based on other criteria, such 
as physical appearance or intellectual ability.  
When a pregnant woman is offered the possibility of 
undergoing prenatal diagnosis for genetic diseases 
through amniocentesis or chorionic villous sampling, it 
implies that selective abortion is an option they will 
consider if the fetus is indeed affected with a genetic 
disease. For some, this option is unacceptable for 
ethical, moral, and/or religious reasons. It raises the 
question of the legal status of the embryo, the definition 
of human life and of a human being. 
IV - Examples of the role of public 
health in genetics 
There are already many examples of the role of public 
health in genetics. Better known examples deal with 
reproductive technologies (prenatal screening, carrier 
screening) and newborn screening. More recent 
examples in the adult setting concern genetic 
susceptibility screening and pharmacogenetics.  
IV - 1. Folic acid and neural tube defects 
Neural tube defects (NTD) account for an important 
part of birth defect-related infantile mortality and 
morbidity. Their incidence tends to be decreasing over 
time (secular trend). During the 1980s, studies have 
shown a decrease in the recurrence of NTD in 
subsequent pregnancies with the use of folic acid for 
women having already had a child with a NTD. Since 
then, studies done in women with no family history f 
NTD have also shown lower incidence rates of children 
born with NTD in women who took folic acid 
supplements. Even though the way in which folic acid 
acts to prevent NTD has not been elucidated, these 
observed findings have led to the hypothesis that folic
acid supplementation would be beneficial to all women 
planning a pregnancy, to prevent the birth of a child 
with a NTD.  
Because the neural tube closes during the fourth week 
of gestation, it is recommended to start folic acid 
supplementation before conception. The minimal dose 
needed to obtain an effect has not been established, but 
the usually recommended daily dose is 400 micrograms 
in women with no specific risk factor, and should be 
started at least 3 months before conception. However, 
supplementation often does not occur, either becaus 
women are not aware of the benefits of folic acid 
supplementation or because pregnancy was not 
planned.  
To address this problem, some countries have decided 
to add folic acid to the food supply, most often in flour. 
This type of public health intervention has occurred in 
the past to prevent other diseases: iodized salt to 
prevent goiter, and vitamin D in milk to prevent rickets. 
Folic acid fortification of flour has not been done 
without controversy. Some fear that folic acid 
fortification will mask vitamin B12 deficiency and 
delay its diagnosis. Others worry about long-term 
effects of a folic acid-fortified diet or about poten ial 
interactions between folic acid and prescribed drugs. 
No study has shown that this fortification strategy 
would be sufficient to reduce the incidence of NTD in 
the population. In spite of all that, many professional 
organizations have declared themselves in favor of 
fortification. Folic acid fortification has been 
established at the end of the 1990s in many developed 
countries, most often in flour. Studies done since 
fortification seem to show a significant reduction n the 
incidence of NTD in the population, even when 
accounting for the secular trend.  
IV - 2. Newborn screening 
Phenylketonuria (PKU) is the first example of 
population-based genetic screening. It was put in place 
in the U.S.A. in the early 1960s, thanks to the 
development by Dr Robert Guthrie of a technique 
allowing the measurement of blood phenylalanine 
levels using blood samples collected on filter paper. 
Samples collected in this way are easy to store and 
ship, and can be preserved for extended periods of 
time. The technique itself is cheap and easy to perform. 
These characteristics have made it possible to develop 
large-scale screening programs. Newborn screening for 
PKU is now performed by the state in most developed 
countries.  
In the wake of newborn screening tests, a screening 
“system” was developed. Today, a newborn screening 
system includes sample collection and shipment to 
screening facilities, performance of the screening test in 
the laboratory, diffusion of test results to parents and 
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referring physicians, and, for newborns with abnormal 
results, rapid access to specialized evaluation and
appropriate care. In parallel, severe quality control 
criteria have been established and voluntary laboratory 
quality control programs are managed by government 
agencies, such as the Center for Disease Control in the 
U.S.A.  
Since the 1960s, other diseases have been added to 
newborn screening panels. The list varies by region, but 
it almost always includes congenital hypothyroidism, 
and often includes galactosemia, tyrosinemia, sickle 
cell anemia, and/or congenital adrenal hyperplasia. For 
all these diseases, a dietary-based or drug-based 
treatment is available to prevent the effects of the
disease or attempt to control their progression, and it 
seems preferable to start these treatments as early as 
possible.  
In the last few years, a new technology, tandem mass 
spectrometry (MS/MS), makes it possible to detect over 
30 metabolic diseases during the newborn period, such
as aminoacidemias, organic acidurias, and urea cycle 
defects, to name a few. The use of this technology f r 
newborn screening is controversial for several reasons. 
Among the diseases that can be detected with MS/MS, 
some have a poorly defined natural history. In those 
cases, it is difficult to predict what will happen to the 
affected newborn and the impact that early diagnosis 
and treatment could have. It is not clear whether di tary 
treatment will be as effective in all cases. However, 
newborn screening using MS/MS would make it 
possible to learn more about these diseases, which 
might otherwise go undetected (even if symptomatic). 
In the U.S.A., advocacy groups formed by parents of 
children with diseases detectable with MS/MS are 
lobbying for the addition of this technology to state-run 
newborn screening programs. Those opposed to using 
MS/MS for newborn screening argue that there is no 
evidence that early diagnosis and treatment of these 
diseases will improve their natural course, which goes 
against the criteria largely used to decide whether or 
not to add new diseases to newborn screening 
programs. They stress that the availability of the 
technology and its capacity to detect disease does n t 
mean that the information it provides is valuable for
newborns.  
Newborn screening for cystic fibrosis is also currently 
debated. Newborn screening programs for cystic 
fibrosis already exist in many regions of the world: in 
Wisconsin and Colorado (USA), in Brittany (France), 
and some regions of the United Kingdom and 
Australia. Some studies have shown that children 
identified through newborn screening achieve better 
nutritional status and/or better respiratory function than 
those diagnosed through symptoms, but these 
differences are mild and tend to disappear over time. 
The main newborn screening criteria, as defined by the 
World Health Organization, state that an effective 
treatment must be available and that the early 
application of that treatment must improve the health 
outcome of the child. Even though long term impact of 
early diagnosis of cystic fibrosis on the evolution f 
disease has not been irrevocably established, some 
argue that early diagnosis is of benefit to parents 
because it avoids unnecessary anxiety related to 
delayed diagnosis in a symptomatic child, and enables 
them to make informed reproductive decisions for 
future pregnancies. The benefit is not for the child 
itself, but for parents, and it is not related to the early 
onset of effective treatment. According to this 
argument, it would be justifiable to screen for genetic 
conditions with no known effective treatment but 
whose early diagnosis would be of value to the parents. 
In the case of cystic fibrosis, early diagnosis can 
possibly be of value to the child, but this would not be 
the case for other diseases for which newborn screening 
has been advocated, such as Duchenne muscular 
dystrophy and Fragile X syndrome.  
IV - 3. Carrier screening in the context of 
reproductive decisions 
The first carrier-screening program for recessive 
diseases was developed in the Ashkenazi Jewish 
communities in New York and Washington, D.C., in 
the U.S.A. With the support of the community and 
religious officials, a carrier-screening program for Tay-
Sachs disease was established in the early 1970s, 
shortly after the discovery of the enzyme whose 
deficiency is the cause of the disease. Tay-Sachs 
disease then had a relatively high prevalence in the 
Ashkenazi Jewish community. This disease causes 
progressive neurodegeneration starting in the first year 
of life and inevitably leading to the child’s death, 
usually by four years of age. Both the community 
members and the health professionals involved agreed 
that this disease is so severe that it would be preferable 
to take measures to avoid the birth of affected children. 
The screening strategy has been adapted to the needs 
and realities of the different communities: in orthdox 
communities where selective abortion was not 
acceptable, premarital screening is performed and 
results are taken into account in the rabbi’s decision to 
bless the marriage or not, which has been deemed 
acceptable by the community. Carrier screening 
programs for Tay-Sachs disease now exist in 
Ashkenazi Jewish communities around the world. 
Thanks to these programs, the incidence of the disease 
has decreased by over 90% in these communities. In 
the wake of this success, other diseases with relativ ly 
high prevalence in Ashkenazi Jewish communities have 
been added to carrier screening panels, such as 
Canavan disease and Gaucher disease, to name a few.  
In response to the success of Tay-Sachs carrier 
screening in Ashkenazi Jewish communities, similar 
programs have been developed in other communities 
where an autosomal recessive disease was highly 
prevalent in children, such as carrier screening for beta-
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thalassemia in Cyprus and Sardinia. These programs 
have also led to drastic reductions in disease prevalence 
in these communities. Carrier screening programs for 
sickle cell anemia in African Americans in the U.S.A. 
in the 1970s have not had the same success, partly 
because the distinction between being a healthy carrier 
and having the disease was not made clear. This had 
led to discrimination against carriers.  
Recently, the American College of Obstetrics and 
Gynecology has recommended that all pregnant women 
be offered carrier screening for cystic fibrosis. This 
recommendation has been questioned by some, because 
screening is routinely offered when pregnancy is 
already ongoing and because cystic fibrosis is not 
considered as severe as Tay-Sachs disease.  
IV - 4. Prenatal screening for aneuploidy and neural 
tube defects 
For a detailed discussion of what is available in 
prenatal diagnosis, see “Prenatal Diagnosis” section.  
In terms of population health, it is of note that prenatal 
screening for chromosomal abnormalities and neural 
tube defects is offered to pregnant women in many 
countries. These screening programs may be targeted at 
women with specific risk factors (i.e. according to 
maternal age), or to all pregnant women. In most caes, 
newborns with chromosomal abnormalities or neural 
tube defect are born of mothers with no specific risk 
factors. A screening test done during pregnancy can 
identify those women at higher risk of carrying a fetus 
with one of these conditions. This blood test, which 
measures a combination of serum and/or ultrasound 
markers, is not a diagnostic test: like all screening tests, 
it tends to be highly sensitive, but not necessarily very 
specific. The role of a screening test is to detect all 
cases of the targeted condition, at the expense of a
certain amount of false positive results. For prenatal 
screening, the test result is usually given as the 
probability that the fetus is affected, and the result is 
considered “positive” when this probability is higher 
than a specific threshold, usually between 1/400 and
1/200. Since this threshold is relatively low, there is 
inevitably a high proportion of false positive result , 
i.e. pregnancies with test results above the threshold 
and considered at high risk of having an affected fetus, 
but whose fetus is actually not affected. In a screening 
context, we tolerate a certain amount of false positive 
results that will have to undergo definitive diagnostic 
testing through amniocentesis and incur the associated 
risk of miscarriage. It is the price to pay to reduce as 
much as possible the rate of false negative results, i.e. a 
result placing the risk below the threshold when the
fetus is actually affected. These screening programs 
have been developed to give women the possibility of 
terminating the pregnancy if the fetus is found to be 
affected. In general, this option is considered 
acceptable because most people consider these 
conditions to be severe enough and prevalent enough to 
justify a population-based screening program. Those 
who consider termination to be unacceptable can select 
out of the screening process. 
IV - 5. Screening for genetic susceptibilities in adults 
Since the sequencing of the human genome, advances 
in genetic knowledge has led us to consider the 
potential use of genetic information to assess indiv dual 
susceptibilty to disease. Although this is not widely 
possible yet, there are some examples of the use of 
genetic tests for that purpose. These examples raise 
questions about the real clinical utility of that type of 
information at the individual level.  
Hereditary hemochromatosis is an autosomal recessive 
disease. Individuals who suffer from this disease can
develop cirrhosis of the liver, diabetes, and 
cardiomyopathy. Symptoms are caused by a defect in 
iron metabolism, which leads to iron deposition in 
tissues. Two main mutations in the hemochromatosis 
gene have been identified, C282Y and H63D. Most 
cases are C282Y homozygotes. Regular phlebotomies 
reduce iron deposition and can help prevent or reduc  
symptoms. For that reason, hemochromatosis is 
considered an ideal target for population-based 
screening. The use of a genetic test as a screening test 
for hereditary hemochromatosis is justified if we 
assume that penetrance of the disease is high, i.e. that 
most C282Y homozygotes will develop symptoms of 
hemochromatosis in their lifetime if untreated, and that 
they would benefit from early diagnosis and preventive 
treatment. Unfortunately, penetrance seems lower than
previously thought: it seems that only a minority of 
C282Y homozygotes actually develop symptoms of 
hemochromatosis in their lifetime. The value of 
population-based genetic screening for 
hemochromatosis is being questioned. It is currently 
recommended to use transferrin saturation level as a 
screening test for hemochromatosis. This is a 
biochemical index of iron overload, and is closer to the 
phenotype of hemochromatosis than the genetic test. 
Factor V Leiden (FVL) is a variant of factor V, a 
coagulation factor. This variant is associated with an 
increased risk of thrombosis. Even though the presence 
of FVL in an individual with a history of thrombosis 
can help explain the cause of the thrombosis, it does 
not usually change immediate treatment or long-term 
management of that individual, who will be treated as 
any other individual with a personal history of 
thrombosis. On the other hand, not all individuals who 
have FVL will develop thrombosis. It is difficult to 
justify population-based screening for FVL, and 
especially to submit them to long-term prophylactic 
anticoagulation treatment, which is associated with 
significant risks of bleeding. Other factors also 
influence the risk of thrombosis in these individuals, 
such as smoking and hormonal therapy, and make it 
difficult to predict risk of thrombosis on an individual 
basis.  






Atlas Genet Cytogenet Oncol Haematol. 2005; 9(1)  
 
91 
As our knowledge of gene-environment interactions 
increases, it might be possible to improve our 
assessment of individual disease susceptibility by using 
predictive models based on combinations of genetic 
and environmental risk factors. For now, the impact of 
genetic susceptibility is difficult to assess, especially on 
an individual basis. 
IV - 6. Pharmacogenetics and ecogenetics 
Pharmacogenetics is a field of genetics focusing on the 
role of genetics in individual variability of drug 
response and side effect occurrence. If we can predict 
the pharmacologic response of a given individual to a 
specific drug based on the presence or absence of a 
given genetic polymorphism, we could adjust dosage 
accordingly. Most genetic polymorphism studied until 
now have been in genes involved in the metabolism or 
elimination of drugs. It is thought that these 
polymorphisms might accelerate or slow drug 
metabolism or drug elimination.  
Ecogenetics is similar to pharmacogenetics, but focuses 
on the role of genetics in explaining the individual 
variability of response to environmental factors 
(carcinogens, pesticides, food products, industria 
pollutants, etc.), instead of response to drugs. This 
information could be used in the workplace to identify 
individual workers at risk of developing complications 
related to occupational exposure to specifc agents. 
There is the danger that this might be used to 
discriminate against those with genetic susceptibility to 
develop complications, who might be refused 
employment. On the other hand, workers at low-risk of 
complications might be exposed to higher levels of the 
agent in question if it gives them a false sense of 
security and protective measures are lessened, which 
would paradoxically put them at higher risk of actually 
developing complications. 
IV - 7. Personalized Health Care and Genetic 
Information 
Some hope that a better understanding of genetic 
variability will help adapt treatments on the basis of an 
individual’s genetic characteristics and the risks and 
benefits of the many treatment options available for 
that individual. This will depend on how fast 
knowledge will grow in pharmacogenetics and 
ecogenetics. In some cases, the treatment will be the 
same, but the dose, duration or timing of treatment will 
be different according to the individual’s genotype. In 
other cases, treatment itself will be tailored for specific 
individual genotypes, targeting specific genetic 
differences. Over time, a better understanding of 
genetic susceptibilities might help target preventive 
measures to individuals who can potentially benefit 
from them the most. But, in the context of increasing 
health care costs, the use of resources to personalize 
health care based on genetic characteristics will have to 
be balanced against its benefits.  
Conclusion 
The impact of genetics in public health is still limited, 
but is expected to grow in the near future, as genetic 
knowledge rapidly increases. Current examples of the 
use of genetics in public health can serve as lessons for 
the future. 
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